Stockholders of Exact Sciences have approved the company’s proposed acquisition by Abbott, with more than 99% of votes cast in favor of the transaction. Pending final regulatory approvals and other closing conditions, the deal is expected to be completed by the end of the second quarter of 2026.
Upon completion, Exact Sciences shareholders will receive $105 in cash per share. The acquisition brings Abbott into Exact Sciences’ portfolio of cancer diagnostics and screening solutions, including stool-based colorectal cancer screening and multi-cancer early detection technologies currently available in the United States.